BioCentury | Oct 6, 2017
Finance

Bargain shopping

...Pharma Corp. (TSX:COM; NASDAQ:CRME) FDA informs the company that its proposed data package for IV Brinavess vernakalant...
BioCentury | Sep 1, 2017
Clinical News

FDA snubs Cardiome's Brinavess resubmission for AF

...NASDAQ:CRME) said FDA informed the company that its proposed data package for IV Brinavess vernakalant (Kynapid, MK-6621...
...adults. Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME), Vancouver, B.C. Product: IV Brinavess vernakalant (Kynapid, MK-6621) Business: Cardiovascular Alicia Parker Brinavess Kynapid MK-6621 Vernakalant...
BioCentury | Aug 21, 2017
Company News

FDA snubs Brinavess resubmission for AF

...Corp. (TSX:COM; NASDAQ:CRME) said FDA informed the company that its proposed data package for IV Brinavess vernakalant...
...other territories for the rapid conversion of recent onset AF to sinus rhythm in adults. Alicia Parker Brinavess Vernakalant...
BioCentury | Jan 26, 2015
Company News

Cardiome, Aspen deal

...Cardiome granted Aspen exclusive rights to commercialize Cardiome’s IV Brinavess vernakalant in South Africa. The mixed ion...
BioCentury | Jan 5, 2015
Company News

Cardiome, Eddingpharm deal

...Cardiome granted Eddingpharm rights to develop and commercialize atrial fibrillation drug IV Brinavess vernakalant in China, including...
BioCentury | Sep 22, 2014
Company News

Cardiome, Eurolab deal

...Cardiome's Correvio International S.a.r.l. subsidiary granted Eurolab exclusive rights to commercialize IV Brinavess vernakalant in Argentina. The...
BioCentury | Mar 31, 2014
Company News

Cardiome, Vianex S.A. sales and marketing update

...Cardiome's Cardiome International A.G. subsidiary granted Vianex rights to commercialize IV Brinavess vernakalant in Greece. The renewable...
BioCentury | Mar 24, 2014
Company News

Cardiome, Logista Pharma sales and marketing update

...Cardiome granted Logista rights to commercialize IV Brinavess vernakalant in Spain. Cardiome said financial terms were not...
BioCentury | Feb 24, 2014
Company News

AOP Orphan, Cardiome sales and marketing update

...Cardiome said IV Brinavess vernakalant for atrial fibrillation (AF) is now available in Switzerland, the Czech Republic...
BioCentury | Feb 24, 2014
Finance

Highlights of weekly biotech stock moves

...through the sale of 1.5 million shares at C$10 in a follow-on. Cardiome markets IV Brinavess vernakalant...
Items per page:
1 - 10 of 163